2 results
Approved WMOCompleted
Objectives:Primary:• To assess progression free survival (PFS) when treated with lanreotide Autogel® 120 mg administered every 14 days based on Response Evaluation Criteria in Solid Tumours (RECIST) v1.0, and according to central review.Secondary:•…
Approved WMORecruiting
1. To test the hypothesis that an age adapted immunosuppressive regimen targeted at reduced immunosuppression with low calcineurin inhibitor exposure will result in improved outcome in elderly recipients of A: kidneys from older deceased donors (…